UPN10 (Figures 1E, 2) was diagnosed with AML (AML with inv (3)(q21.3q26.2); GATA2, MECOM; ELN adverse risk category) in 2002 and received intensive induction therapy and subsequently underwent allogeneic haploidentical HCT with an ex vivo/in vivo TCD graft (CD34 selection + ATG) in CR1 3 months later. This evidence concerns the gene MECOM and acute myeloid leukemia.